OBJECTIVES: The overall aim was to increase understanding of men's decision-making about prostate-specific antigen (PSA) testing and subsequent biopsy. METHODS: This qualitative interview study was nested within the primary care-based Prostate Testing for Cancer and Treatment (ProtecT) trial in nine United Kingdom areas (ISRCTN number: 20141297). Fifty-eight men aged 50-69 yr (mean: 62 yr), accepting (n=14) or not responding (n=7) to invitations for PSA testing and accepting (n=24) or refusing (n=13) prostate biopsy were interviewed. RESULTS: In this study, men accepting PSA testing and biopsy reported positively on their experiences, regardless of the final outcome. PSA testing was considered routine and biopsy acceptable to most men. Men both responding and not responding to PSA testing often perceived themselves to be at low risk for prostate cancer. Men refusing biopsy also tended to perceive themselves to be at low risk and many were anxious about the test itself. Misunderstandings about the relationship between urinary symptoms and risk of prostate cancer were identified. CONCLUSIONS: Most men found PSA testing and biopsy acceptable, but perceptions of risk were not always accurate and the provision of more tailored information may help facilitate informed decision-making.
OBJECTIVES: The overall aim was to increase understanding of men's decision-making about prostate-specific antigen (PSA) testing and subsequent biopsy. METHODS: This qualitative interview study was nested within the primary care-based Prostate Testing for Cancer and Treatment (ProtecT) trial in nine United Kingdom areas (ISRCTN number: 20141297). Fifty-eight men aged 50-69 yr (mean: 62 yr), accepting (n=14) or not responding (n=7) to invitations for PSA testing and accepting (n=24) or refusing (n=13) prostate biopsy were interviewed. RESULTS: In this study, men accepting PSA testing and biopsy reported positively on their experiences, regardless of the final outcome. PSA testing was considered routine and biopsy acceptable to most men. Men both responding and not responding to PSA testing often perceived themselves to be at low risk for prostate cancer. Men refusing biopsy also tended to perceive themselves to be at low risk and many were anxious about the test itself. Misunderstandings about the relationship between urinary symptoms and risk of prostate cancer were identified. CONCLUSIONS: Most men found PSA testing and biopsy acceptable, but perceptions of risk were not always accurate and the provision of more tailored information may help facilitate informed decision-making.
Authors: Ali S Murad; George Davey Smith; Sarah J Lewis; Angela Cox; Jenny L Donovan; David E Neal; Freddie C Hamdy; Richard M Martin Journal: Int J Mol Epidemiol Genet Date: 2010-04-01
Authors: R C Macefield; C Metcalfe; J A Lane; J L Donovan; K N L Avery; J M Blazeby; L Down; D E Neal; F C Hamdy; K Vedhara Journal: Br J Cancer Date: 2010-04-06 Impact factor: 7.640
Authors: Sarah J Lewis; Ali Murad; Lina Chen; George Davey Smith; Jenny Donovan; Tom Palmer; Freddie Hamdy; David Neal; J Athene Lane; Michael Davis; Angela Cox; Richard M Martin Journal: PLoS One Date: 2010-10-19 Impact factor: 3.240
Authors: Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal Journal: Health Technol Assess Date: 2020-08 Impact factor: 4.014
Authors: Winnie K W So; Kai Chow Choi; Winnie P Y Tang; Paul C W Lee; Ann T Y Shiu; Simone S M Ho; Helen Y L Chan; Wendy W T Lam; William B Goggins; Carmen W H Chan Journal: Cancer Biol Med Date: 2014-03 Impact factor: 4.248